On July 18, 2018 BioCure Technology Inc. (CSE:CURE, OTCQB;BICTF) ("BioCure" or the "Company") reported that its wholly owned subsidiary BiocurePharm Corporation ("BP Korea"), has implemented the preclinical trial of Interferon Beta 1b since late 2017 and is pleased to update shareholders on their progress (Press release, Biocure Technology, JUL 18, 2018, View Source [SID1234628761]). BP Korea announces that it has completed most of the toxicity testing and has developed MCB (Master Cell Bank) and WCB (Working Cell Bank). Currently, BP Korea is in the middle of in-Vivo potency test. The Company has already produced 35,000 vials of Interferon Beta 1b for their pre-clinical trial and stability test at the GMP manufacturing facility in Korea. BP Korea expects the pre-clinical trial shall be completed by the end of Q1, 2019 and will advance to clinical trial in 3Q 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sang Mok Lee, CEO comments "We are making every effort to commercialize Interferon Beta, 1b, the first Biosimilar of the Company by 2021. BP Korea is in discussion with potential foreign partners to implement a clinical trial and produce Interferon Beta 1b in their countries through a partnership, once the pre-clinical trial is completed in Korea. We strongly believe that such partnerships could provide patients in those countries with much more affordable access to Interferon Beta."

On July 18, 2018 DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, reported that they have entered into a license agreement and research collaboration (Press release, DCPrime, JUL 18, 2018, View Source [SID1234529907]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, DCprime has obtained the global research and commercialization rights to certain process development patents owned by Glycotope. In addition, the companies have initiated a research collaboration to evaluate novel immunotherapeutic approaches to solid tumours, based on the combination of their proprietary technologies.

Henner Kollenberg, Managing Director, Glycotope commented: "This is an exciting opportunity and we look forward to working with DCprime. Through this collaboration we will look to draw on DCprime’s expertise in the development of dendritic cell therapies and combine this with our own knowledge of glyco-biology to evaluate potential new immunotherapies."

Erik Manting, CEO of DCprime added: "It is a pleasure to work with Glycotope based on their strong basis in process development and immuno-oncology. This collaboration allows us to pursue new and innovative combination therapies based on DCOne and immunomodulatory antibodies."

On July 18, 2018 Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, reported that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC ("TD2") (Press release, Atossa Genetics, JUL 18, 2018, View Source [SID1234527758]). The purpose of the initial study is to develop and validate preclinical methods of using Atossa’s proprietary intraductal microcatheter technology to administer immunotherapy to the site of tumor initiation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While there has been recent success treating blood cancers with chimeric antigen receptor therapy (or, CAR-T), there has not been much success using CAR-T to treat solid tumors like breast cancer," commented Steve Quay, Ph.D., MD, President and CEO of Atossa. "We are, however, encouraged by a recent case study reported June 4, 2018 in Nature Medicine (N. Zacharakis, et al.), in which a patient with metastatic breast cancer who was not responding to chemotherapy had complete tumor regression 22 months after being treated with an intravenous infusion of eighty billion T-cells and interleukin. We believe our proprietary intraductal microcatheter technology may provide a unique and more efficacious and cost-effective treatment method by delivering a significantly smaller number of T-cells directly to the site of the cancer prior to metastasis, rather than through the blood stream, where they are diluted into the entire body. These studies are the first of several steps to develop our intraductal microcatheter technology to treat breast cancer with cell-based immunotherapy, such as CAR-T. These pre-clinical studies will form the basis for the design of human studies, with the ultimate goal of treating breast cancer by administering an immunotherapy with our proprietary microcatheter technology," added Dr. Quay.

The studies are being conducted for Atossa by Translational Drug Development, LLC, which is an oncology development organization that provides innovative services and is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases.

On July 18, 2018 Clovis Oncology, Inc. (NASDAQ: CLVS) reported that it will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.S. financial markets (Press release, Clovis Oncology, JUL 18, 2018, View Source [SID1234527759]). Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be available for 30 days.

Conference Call Details

Clovis will hold a conference call to discuss second quarter 2018 results on August 1 at 4:30 p.m. ET. The conference call will be simultaneously webcast on the Company’s website at www.clovisoncology.com, and archived for future review. Dial-in numbers for the conference call are as follows: US participants 866.489.9022, International participants 678.509.7575, conference ID: 9289064.

(Filing, Annual, Sellas Life Sciences, 2017, JUL 18, 2018, View Source [SID1234527760])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!